文献速递基础与转化研究临床试验与 GCP

登革病毒受控人类感染试验揭示既往免疫影响病毒复制与广谱保护应答

Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses.
PubMed 文献 · Sci Transl Med · 2026-10-28

该1期临床试验对45名健康成人进行异型全长减毒活病毒二次感染挑战,发现二次感染导致更高病毒血症、中和抗体和保护性T细胞应答;但基线抗体最能增强病毒体外复制者出现免疫激活延迟、最高病毒血症及CD8+ T细胞和抗体衰减,而针对多血清型NS1的高基线抗体预测早期干扰素应答和持久保护。

要点

  • 二次感染挑战较初次和三次感染诱导更高病毒血症和免疫原性。
  • 基线抗体增强病毒体外复制者出现最高病毒血症和免疫失调。
  • 多血清型NS1高基线抗体预测病毒控制与持久B/T细胞应答。

核心结论

  • 登革病毒受控人类感染试验可区分协调与失调的急性免疫应答及其对免疫原性的影响。

研究设计与样本

  • 1期临床试验纳入45名健康成人,比较初次、二次和三次异型全长减毒活病毒挑战感染。

主要发现

  • 病毒血症与更多但仍轻微的临床体征和症状相关。
  • 二次感染导致更高病毒血症、中和抗体和保护性T细胞应答。
  • 基线抗体最能增强病毒体外复制者出现炎症和适应性免疫激活延迟、最高病毒血症、强急性免疫应答以及强效CD8+ T细胞和抗体衰减。
  • 针对多血清型非结构蛋白1的高基线抗体预测早期干扰素和平衡免疫激活、病毒血症控制及持久强效B和T细胞产生。
  • 基线具有强效中和抗体和IFN-γ+ T细胞者病毒复制极少。

临床怎么用

  • 基线抗体功能(而非仅滴度)可帮助识别登革感染高风险个体。
  • 多血清型NS1抗体可作为广谱保护性疫苗设计的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dengue is the canonical viral disease for which immune history is a determinant of protective versus pathogenic responses and immunogenicity. Yet, because of limitations in animal models and clinical presentation after peak viremia, how preinfection and early immune responses affect dengue outcome is not confirmed. We conducted a phase 1 clinical trial with 45 healthy adults to test whether secondary infection challenge with a heterotypic, full-length, attenuated virus increases viremia and immunogenicity compared with primary and tertiary infection. Viremia was associated with more, but still mild, clinical signs and symptoms, and secondary infection resulted in greater viremia, neutralizing antibodies, and protective T cell responses. However, those whose baseline antibodies most efficiently increased dengue virus replication in an in vitro assay experienced delayed inflammatory and adaptive immune activation, the highest viremia, strong acute immune responses, and waning of potent CD8+ T cells and antibodies. In contrast, higher baseline antibodies against the nonstructural protein 1 of multiple serotypes predicted early interferon and balanced immune activation, viremia control, and development of enduring, potent B and T cells, revealing how vaccines can induce broad, long-lasting protection. Last, individuals with potent and neutralizing antibodies and IFN-γ+ T cells at baseline experienced minimal viral replication. Together, these findings demonstrate that controlled human challenge with dengue virus can delineate coordinated versus dysregulated acute immune responses and their effects on immunogenicity, informing therapeutic and vaccine strategies for dengue and other viral diseases.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Odio CD, Aogo RA, Firdous S, et al. Dengue virus controlled human challenge reveals that preexisting immunity shapes viral replication and broadly protective responses. Sci Transl Med. 2026. PMID: 42950018. doi:10.1126/scitranslmed.aei5117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。